Brief: Surface Oncology Announces SRF617 And SRF388 Will Advance To Combination And Expansion Stages Of Ongoing Phase 1 Clinical Trials
13/11/2020 12:13
Nov 13 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY ANNOUNCES SRF617 AND SRF388 WILL ADVANCE
TO
COMBINATION AND EXPANSION STAGES OF ONGOING PHASE 1 CLINICAL
TRIALS
* SURFACE ONCOLOGY INC - DETAILED CLINICAL DATA FOR EACH
PROGRAM
TO BE PRESENTED AT A MEDICAL CONFERENCE IN FIRST HALF OF 2021
Source text for Eikon: ID:nGNX94l2ZY
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing